Abstract: The present disclosure generally relates to nanoparticles comprising an antibody, such as an anti-PD-1 antibody. Other aspects include methods of making and using such nanoparticles. In an embodiment, the nanoparticles comprise a diblock poly(lactic) acid-poly(ethylene)glycol (PLA-PEG) copolymer, a chemotherapeutic agent, and a prostate-specific membrane antigen (PSMA) targeting ligand.

Abstract: Disclosed herein are compositions for treating and preventing diseases such as myeloma and lymphoma, where the compositions include a biocompatible, therapeutic polymeric nanoparticle having a boronate ester compound or a peptide boronic acid compound, and a biodegradable polymer. Methods of use of the therapeutic compositions are also disclosed.

Abstract: The present invention is directed to the administration of a cannabinoid aerosol formulation using a soft mist inhaler (SMI) with reduced cannabinoid-related irritation and/or coughing. Described is an aerosol formulation comprising a cannabinoid in an ethanol solution and further comprising saccharin or a salt thereof, an aerosol formulation comprising a cannabinoid in a solution comprising ethanol and saline, and methods for the use thereof.

Abstract: The invention provides for compositions comprising one or more or at least two active ingredient(s), e.g., a cannabinoid, cannabinoid extract, terpene, or terpene extract. The invention includes cannabinoid formulations, including self-emulsifying formulations and micellar dispersions, as well as methods of making and using the same. Some formulations comprise a cannabinoid and surfactant. The formulations have improved dissolution, stability, absorption and/or oral bioavailability. Some of the formulations are rapid dispersing formulations.

Abstract: The invention is directed to a nanoprecipitate comprising a cannabinoid or a terpene, or combination thereof, a process of preparing the nanoprecipitate, and oral formulations comprising the nanoprecipitate, including beverage additives and edibles.

Abstract: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of pemetrexed; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.

Abstract: The invention provides for cannabinoid formulations, including self-emulsifying formulations and micellar dispersions, as well as methods of making and using the same. The formulations comprise a cannabinoid and surfactant. The formulations have improved dissolution, stability, and pharmacokinetics, including absorption and/or oral bioavailability. The invention also provides for formulations comprising at least one active ingredient, including self-emulsifying formulations and micellar dispersions, as well as methods of making and using the same. The formulations comprise a least one active ingredient and surfactant.

Abstract: Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer-EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.

Abstract: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a antibiotic therapeutic agent; about 0.05 to about 30 weight percent of a hydrophobic acid; and about 35 to about 99.75 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol or diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol. Other aspects include methods of making such nanoparticles.

Abstract: Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer—EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.

Abstract: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of pemetrexed; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.

Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.

Abstract: The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.

Abstract: The present disclosure relates in part to methods of treating cholangiocarcinoma or tonsillar cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein nanoparticle composition comprises nanoparticles.

Abstract: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of pemetrexed; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.

Abstract: Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer—EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.

Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.

Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer.

Abstract: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.